S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
S&P 500   4,240.27 (+0.26%)
DOW   32,992.06 (-0.03%)
QQQ   356.81 (+0.53%)
AAPL   172.20 (-0.12%)
MSFT   316.44 (+0.97%)
META   300.48 (-0.15%)
GOOGL   133.54 (+0.84%)
AMZN   126.27 (+1.24%)
TSLA   249.85 (+1.35%)
NVDA   436.99 (+0.42%)
NIO   8.56 (-0.58%)
BABA   84.54 (+0.00%)
AMD   100.76 (+0.68%)
T   14.70 (-0.54%)
F   11.99 (-0.66%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.40%)
GE   107.52 (-0.22%)
DIS   79.69 (+0.19%)
AMC   7.97 (+1.53%)
PFE   34.06 (+0.47%)
PYPL   58.21 (+1.59%)
NFLX   376.06 (-0.18%)
NYSE:ENZ

Enzo Biochem (ENZ) Stock Forecast, Price & News

$1.34
-0.05 (-3.60%)
(As of 09:30 AM ET)
Compare
Today's Range
$1.34
$1.34
50-Day Range
$1.30
$1.64
52-Week Range
$1.00
$2.74
Volume
1,270 shs
Average Volume
439,887 shs
Market Capitalization
$66.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ENZ stock logo

About Enzo Biochem (NYSE:ENZ) Stock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.

ENZ Price History

ENZ Stock News Headlines

Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Enzo Biochem CEO Hamid Erfanian Resigns After Two Years
Enzo Biochem (NYSE: ENZ)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
Enzo Biochem cuts price for labs assets to Labcorp
Short Volatility Alert: Enzo Biochem Inc
Enzo Biochem reports Q3 results
See More Headlines
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Company Calendar

Last Earnings
10/15/2019
Today
10/04/2023
Next Earnings (Estimated)
10/13/2023
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
465
Year Founded
1976

Profitability

Net Income
$-18,260,000.00
Pretax Margin
-64.19%

Debt

Sales & Book Value

Annual Sales
$107.07 million
Book Value
$1.12 per share

Miscellaneous

Free Float
41,965,000
Market Cap
$68.03 million
Optionable
Optionable
Beta
0.96

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Ms. Kara Cannon (Age 54)
    Interim CEO & COO
    Comp: $474.28k
  • Dr. Elazar Rabbani Ph.D. (Age 80)
    Co-Founder & Director
    Comp: $3.23M
  • Ms. Patricia Eckert CPA (Age 46)
    Interim Chief Financial Officer
  • Mr. Matthew Kupferberg (Age 57)
    Gen. Counsel & Sec.













ENZ Stock - Frequently Asked Questions

How have ENZ shares performed in 2023?

Enzo Biochem's stock was trading at $1.43 at the beginning of 2023. Since then, ENZ stock has decreased by 4.2% and is now trading at $1.37.
View the best growth stocks for 2023 here
.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,670,000 shares, an increase of 13.6% from the August 31st total of 1,470,000 shares. Based on an average daily volume of 335,100 shares, the days-to-cover ratio is currently 5.0 days. Approximately 4.8% of the shares of the stock are short sold.
View Enzo Biochem's Short Interest
.

When is Enzo Biochem's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 13th 2023.
View our ENZ earnings forecast
.

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) released its earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.03. The medical research company had revenue of $20.92 million for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 116.13% and a negative net margin of 64.19%.

What other stocks do shareholders of Enzo Biochem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enzo Biochem investors own include OneLife Technologies (OLMM), Gilead Sciences (GILD), OPKO Health (OPK), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Pfizer (PFE), Advanced Micro Devices (AMD), Amarin (AMRN) and Micron Technology (MU).

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How do I buy shares of Enzo Biochem?

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $1.37.

How much money does Enzo Biochem make?

Enzo Biochem (NYSE:ENZ) has a market capitalization of $68.03 million and generates $107.07 million in revenue each year. The medical research company earns $-18,260,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Enzo Biochem have?

The company employs 465 workers across the globe.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The official website for the company is www.enzo.com. The medical research company can be reached via phone at (212) 583-0100, via email at ir@enzo.com, or via fax at 212-679-7999.

This page (NYSE:ENZ) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -